Rani Therapeutics Holdings (Rani Therapeutics Holdings) Total Inventories : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings Total Inventories?

Rani Therapeutics Holdings's total inventories for the quarter that ended in Mar. 2024 was $0.00 Mil. Rani Therapeutics Holdings's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Rani Therapeutics Holdings's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.25.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Rani Therapeutics Holdings Total Inventories Historical Data

The historical data trend for Rani Therapeutics Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rani Therapeutics Holdings Total Inventories Chart

Rani Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Rani Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial													-	-	-	-	-

Rani Therapeutics Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Rani Therapeutics Holdings (NAS:RANI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Rani Therapeutics Holdings's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(39.581	+	0.75 * 0	+	0.5 * 0	-	38.977
-	0	-	7.137)	/	26.294
=	-0.25

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Rani Therapeutics Holdings's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Rani Therapeutics Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Rani Therapeutics Holdings's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Rani Therapeutics Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Rani Therapeutics Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Rani Therapeutics Holdings (Rani Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

2051 Ringwood Avenue, San Jose, CA, USA, 95131

Website

https://www.ranitherapeutics.com

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.

Executives

Talat Imran	director, officer: CEO	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Cone Investments Limited Partnership	10 percent owner	AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Quiroga Cortes Isidoro Alfonso	10 percent owner	9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Kate Mckinley	officer: CHIEF BUSINESS OFFICER	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Svai S Sanford	officer: CFO	C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen	officer: General Counsel	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim	officer: Chief Scientific Officer	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership	10 percent owner	LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran	director
Andrew Farquharson	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono	director
Lisa Ann Rometty	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131